Generic biologics are coming, but savings may not be dramatic

12/8/2011 | ScientificAmerican.com

By the end of this year, the FDA is set to issue a pathway for the approval of generic forms of biological drugs. However, even though the generic biologics, termed biosimilars, will cost less than brand-name biologics, keeping costs down won't be easy, because the manufacturing process of biologics is inherently more complicated than that of other pharmaceuticals. The FDA's biotechnology products office is hoping that the evolution of better analytical tools will make it easier for the agency to verify that biosimilars are structurally and functionally similar to their brand-name counterparts.

View Full Article in:

ScientificAmerican.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC